This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Jun 18;377(9783):2060-2.

doi: 10.1016/S0140-6736(11)60788-5. Epub 2011 Jun 5.

First-line treatment of advanced colorectal cancer

Madeleine Hewish¹, David Cunningham

Affiliations

PMID: 21641637
DOI: 10.1016/S0140-6736(11)60788-5

Comment

First-line treatment of advanced colorectal cancer

Madeleine Hewish et al. Lancet. 2011.

. 2011 Jun 18;377(9783):2060-2.

doi: 10.1016/S0140-6736(11)60788-5. Epub 2011 Jun 5.

Authors

Madeleine Hewish¹, David Cunningham

Affiliation

¹ The Royal Marsden Hospitals NHS Trust, London and Surrey, Sutton, Surrey SM2 5PT, UK.

PMID: 21641637
DOI: 10.1016/S0140-6736(11)60788-5

Erratum in

Lancet. 2011 Jun 18;377(9783):2084

No abstract available

PubMed Disclaimer

Comment on

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators. Maughan TS, et al. Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5. Lancet. 2011. PMID: 21641636 Free PMC article. Clinical Trial.

Similar articles

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators. Maughan TS, et al. Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5. Lancet. 2011. PMID: 21641636 Free PMC article. Clinical Trial.
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Tol J, et al. N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. N Engl J Med. 2009. PMID: 19196673 Clinical Trial.
Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
Gibson TB, Grothey E, Chu E. Gibson TB, et al. Clin Colorectal Cancer. 2008 Jul;7(4):233-9. doi: 10.1016/s1533-0028(11)70426-1. Clin Colorectal Cancer. 2008. PMID: 18650191 No abstract available.
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Lee JJ, Chu E. Lee JJ, et al. Clin Colorectal Cancer. 2007 Dec;7 Suppl 1:S16-20. doi: 10.3816/ccc.2008.s.003. Clin Colorectal Cancer. 2007. PMID: 18361802 Review.
[The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Landherr L, Nagykálnai T. Landherr L, et al. Magy Onkol. 2009 Sep;53(3):237-46. doi: 10.1556/MOnkol.53.2009.3.1. Magy Onkol. 2009. PMID: 19793687 Review. Hungarian.

See all similar articles

Cited by

Boosting of the enhanced permeability and retention effect with nanocapsules improves the therapeutic effects of cetuximab.
Yang C, Tan Y, Qi H, Zhou J, Long L, Zhan Q, Wang Y, Yuan X, Kang C. Yang C, et al. Cancer Biol Med. 2020 May 15;17(2):433-443. doi: 10.20892/j.issn.2095-3941.2019.0292. Cancer Biol Med. 2020. PMID: 32587779 Free PMC article.
Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases.
Romesser PB, Tyagi N, Crane CH. Romesser PB, et al. Cancers (Basel). 2021 Apr 1;13(7):1636. doi: 10.3390/cancers13071636. Cancers (Basel). 2021. PMID: 33915810 Free PMC article. Review.
Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer.
Park JJ, Lee M. Park JJ, et al. Gut Liver. 2013 Nov;7(6):629-41. doi: 10.5009/gnl.2013.7.6.629. Epub 2013 Nov 11. Gut Liver. 2013. PMID: 24312702 Free PMC article. Review.
Radiotherapeutic treatment options for oligotopic malignant liver lesions.
Wust P, Beck M, Dabrowski R, Neumann O, Zschaeck S, Kaul D, Modest DP, Stromberger C, Gebauer B, Ghadjar P. Wust P, et al. Radiat Oncol. 2021 Mar 16;16(1):51. doi: 10.1186/s13014-021-01779-5. Radiat Oncol. 2021. PMID: 33726751 Free PMC article.
The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W, Li J, Zhou L, Han J, Liu R, Zhang H, Ning T, Gao Z, Liu B, Chen X, Ba Y. Sun W, et al. Theranostics. 2020 Jan 12;10(5):1981-1996. doi: 10.7150/thno.37621. eCollection 2020. Theranostics. 2020. PMID: 32104496 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

G0802325/MRC_/Medical Research Council/United Kingdom

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information